Metabolic reprogramming of NAD+ regulation via inhibition of CD38 has been proposed as a strategy for improving the efficacy of immune-based therapies and appears to play a significant role in the regulation of metabolism and immunomodulation of the tumor microenvironment [28, 45–47]. Here, CD38 is linked to neoplasm.